IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.17 -1.45%

-$0.45 today

Market cap
$2.53B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.42M

Average 1.44M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$71.10M

FY 2025 · Annual

Investing Cash Flow

$69.98M

FY 2025 · Annual

Financing Cash Flow

$29.78M

FY 2025 · Annual

-95.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
Deferred Income Tax00000
Stock-Based Compensation8.24M11.63M18.49M34.75M46.12M
Change in Working Capital(17.81M)(41.56M)(13.21M)11.55M1.87M
Accounts Receivables774K892K193K15K0
Inventory3.79M0000
Accounts Payables1.17M1.86M2.64M8.28M2.7M
Other Working Capital(23.54M)(44.31M)(16.04M)3.25M(829K)
Other Non-Cash Items1.83M(695K)(11.55M)(23.23M)(9.98M)
Operating Cash Flow(55.78M)(87.18M)(115.22M)(247.58M)(71.1M)
Capital Expenditures(2.64M)(3.44M)(2.37M)(3.86M)(2.37M)
Acquisitions (Net)67.02M33.4M000
Purchases of Investments(315M)(255.81M)(595.98M)(1.19B)(607.89M)
Sales of Investments247.97M225.85M439.89M692.61M680.23M
Other Investing Activities(67.02M)(33.4M)000
Investing Cash Flow(69.67M)(33.4M)(158.46M)(502.56M)69.98M
Debt Repayment00000
Common Stock Issued143.25M94.96M309.76M654.23M29.78M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.2M2.2M10.77M13.92M0
Financing Cash Flow145.45M97.17M362.72M677.55M29.78M
Effect of Forex Changes0000(210K)
Net Change in Cash20.01M(23.41M)89.04M(72.59M)28.45M
Free Cash Flow(58.42M)(90.62M)(117.59M)(251.44M)(73.47M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$113.7M
+ D&A$4.6M
+ Stock-Based Comp$46.1M
+ Deferred Tax$0
+ Working Capital$1.9M
- Other Non-Cash-$10.0M
= Operating Cash Flow-$71.1M
- Capex-$2.4M
= Free Cash Flow-$73.5M

Analysis

FY2025 free cash flow is -$73.5M. FCF conversion is 64.6% of net income. Operating cash flow was -$71.1M, with capex of -$2.4M. The largest bridge item is Stock-Based Comp at $46.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-8S-8 filingNov 3, 2026
8-KCurrent reportNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipOct 8, 2026
SC 13GSC 13G filingAug 14, 2026

Does IDYA generate free cash flow?

IDEAYA Biosciences, Inc. (IDYA) generated -$73.47M of free cash flow in fiscal 2025.

How much operating cash flow does IDYA produce?

Operating cash flow was -$71.10M, before capital expenditures of $2.37M.